Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 6/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15142098 | 0.87 | CYP11B1 (0.42) | CYP11B1CYP11B2TOP2ATOP2BALDH1A1 | |
| SCHEMBL21452277 | 0.83 | CYP11B1 (0.43) | CYP11B1CYP11B2TOP2ATOP2BALDH1A1 | |
| SCHEMBL23623878 | 0.78 | CYP11B1 (0.48) | CYP11B1CYP11B2ALDH1A1MAPTCD274 | |
| SCHEMBL21618583 | 0.77 | CD274 (0.40) | CYP11B1CYP11B2TOP2ATOP2BCD274 | |
| SCHEMBL21233981 | 0.76 | GRIN2B (0.38) | CYP11B1CYP11B2CD274PDCD1LG2MGLL | |
| SCHEMBL21224480 | 0.76 | GRIN2B (0.38) | CYP11B1CYP11B2CD274PDCD1LG2MGLL | |
| SCHEMBL24562931 | 0.75 | CYP11B1 (0.42) | CYP11B1CYP11B2CD274PDCD1LG2PDCD1 | |
| SCHEMBL24004287 | 0.73 | CYP11B1 (0.41) | CYP11B1CYP11B2ALDH1A1CD274PDCD1LG2 | |
| SCHEMBL21673296 | 0.73 | CYP11B1 (0.44) | CYP11B1CYP11B2CD274PDCD1LG2PDCD1 | |
| SCHEMBL30620955 | 0.73 | CYP11B1 (0.38) | CYP11B1CYP11B2CD274PDCD1LG2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CYP11B1 1842/4885CYP11B2 2218/4885TOP2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.